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Common Causes of Postmenopausal Bleeding in Korean 
Women: 10-Year Outcomes from a Single Medical Center
The common causes of postmenopausal bleeding (PMB), according to the data from the 
western world, are atrophy, hormone replacement therapy (HRT), endometrial cancer, etc. 
We conducted a retrospective study to assess whether the causes of PMB in Korean 
postmenopausal women are similar to those already known. This retrospective study used 
10-year medical records (March 2005 to December 2014) of 792 PMB women in the Yonsei 
University Health System. The data were divided into 2 categories by 5-year intervals to 
compare the differences between the 2 periods. The most common cause of PMB in 
Korean women was atrophy (51.1%). Polyps and HRT were the second, followed by 
anticoagulant medications, cervical cancer, and endometrial cancer. The proportion of 
patients with cervical cancer significantly decreased during the second half of the decade 
(8.7% vs. 5.2%; P = 0.048). Although no significant change was noted for HRT, its rank 
was higher during the latter 5-year period. Only the most common cause of PMB was the 
same as the conventional data. Interestingly, the proportion of patients with cervical 
cancer decreased during the latter half of the decade, reflecting the changes in the nation’s 
cancer prevalence rate, while the use of HRT increased.
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INTRODUCTION
Postmenopausal bleeding (PMB) is a common medical prob-
lem with a prevalence rate as high as 10% in the general popu-
lation (1,2). It is important to evaluate the cause of PMB because 
of its association with gynecologic malignancies (2-6). Early di-
agnosis may help improve survival rates, hence several diagnos-
tic tools such as transvaginal ultrasonography or hysteroscopy 
have been implemented for early and accurate detection of ma-
lignancy (1,4,7-10). Recently, cancer prevalence rates have been 
changing due to better cancer screening modalities and health 
insurance coverage. Especially, cervical cancer incidence has 
been steadily decreasing, whereas that of endometrial cancer 
has been modestly increasing worldwide according to recent 
statistics (11-14). These changes in cancer incidence rates may 
also affect the number of patients per cause of PMB.
 The common causes of PMB according to the data from the 
West are vaginal or endometrial atrophy, hormone replacement 
therapy (HRT), endometrial cancer, endometrial or cervical pol-
yps, endometrial hyperplasia, and other miscellaneous diseas-
es (15,16). However, data on causes of PMB in Asia are lacking. 
Therefore, we conducted a retrospective study to assess wheth-
er the causes of PMB in Korean postmenopausal women are 
similar to that already known.
MATERIALS AND METHODS
Women who were at least 45 years old and stopped menstruat-
ing for more than 12 months were defined as postmenopausal. 
Hospital database searching was done using the keyword “post-
menopausal bleeding” or “vaginal bleeding” in the diagnosis. 
Total of 1,769 women were selected initially, and after exclud-
ing those with the exclusion criteria as mentioned below, a total 
of 792 postmenopausal patients who attended Yonsei Universi-
ty Health System, Seoul, Korea with vaginal bleeding as the chief 
complaint were enrolled in this study. Retrospective evaluation 
of the 10-year medical records (March 2005 to December 2014) 
of the study population was conducted. The data were arranged 
into the following categories: history, diagnosis, method used 
for confirmation of diagnosis, sonographic data, and previously 
prescribed medication. Since a single patient may have several 
diagnoses, total number of cases exceeded the number of pa-
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tients. Therefore, total of 897 diagnoses were counted. All data 
were entered into an Excel database (Microsoft, Seattle, WA, USA) 
for analysis.
 The exclusion criteria were as follows: unidentified patholo-
gy, no specific diagnosis, and trauma (i.e. previous large loop 
excision of the transformation zone [LLETZ] status, biopsy sta-
tus, etc.). Patients with other medical conditions such as Behçet’s 
disease or pancytopenia were also excluded. The most common-
ly known etiology for PMB, vaginal or endometrial atrophy, was 
defined by sonographic data as an endometrial thickness of less 
than 5 mm, and by the histopathological results from biopsy or 
Pap smear.
 The study population was divided into 2 groups: patients who 
visited our hospital during the first 5 years (2005–2009) and those 
who came during the latter 5 years (2010–2014). The 2 groups’ 
PMB causes were statistically compared using Pearson’s χ2 test. 
Statistical analysis was conducted with SPSS software ver.20 (IBM, 
Armonk, NY, USA). Statistical significance was set at P < 0.05.
Ethics statement
This study was conducted according to the tenants of the Dec-
laration of Helsinki and was approved by the Institutional Re-
view Board at Yonsei University Health System, Severance Hos-
pital (4-2015-1005). Written informed consent was waived due 
to the study’s retrospective nature and because the study data 
did not include any personal identifying information.
RESULTS
The most common cause of PMB in Korean women was vagi-
nal or endometrial atrophy (51.1%). Endometrial and cervical 
polyps were the second common cause (11.5%). HRT was also 
on the second rank (11.5%), followed by anticoagulant medica-
tions (7.0%), cervical cancer (6.9%), endometrial cancer (5.7%), 
and other miscellaneous causes (Table 1). Although there were 
many tibolone users in the HRT group, the most common HRT 
medication that induced PMB was the combined estrogen and 
progesterone derivatives (EPT). For the anticoagulant medica-
tion group, aspirin was the most common medication followed 
by coumadin.
 Out of the 792 patients included in the study population, 402 
patients were allocated to the first 5-year group and 390 patients 
to the latter group. The mean age was slightly older in the latter 
5-year group (62.1 ± 9.16 vs. 61.9 ± 9.26 years). The 3 most com-
mon causes were similar between the first and second halves of 
the decade. However, the percentage of cervical cancer decreased 
significantly during the second half of the decade (5.2% vs. 8.7%; 
P = 0.048). In addition, the percentage of endometrial cancer 
also decreased in the latter group but without significance (5.4% 
vs. 6.0%). Although no significant change in percentage was not-
ed for HRT, its rank was higher during the latter half of the de-
cade (2nd vs. 3rd). Most of the HRT included continuous pro-
gesterone treatment. The cyclic progesterone treatment was used 
by only 6 patients (12.5% of HRT users) during the first half de-
cade, and only 5 patients (9.1% of HRT users) in the latter half. 
Furthermore, there were more anticoagulant users in the latter 
group (9.0% vs. 5.1%; P = 0.023).
DISCUSSION
This study evaluated the common causes of PMB among Kore-
an postmenopausal women and apparently, has shown differ-
ent results compared to the previously known causes from Cau-
casians and other ethnicities. The leading cause of PMB was 
vaginal or endometrial atrophy, but all the other causes were 
differently ranked. Endometrial and cervical polyps were more 
prevalent and endometrial cancer was relatively rare. Although 
requiring further studies, a report from Hong Kong (3) showed 
that the prevalence of endometrial cancer among women with 
PMB in Hong Kong was 3.8%, which is much lower than the 
previously reported 10% in developed countries (17). This is 
one representative example which depicts the possibility that 
endometrial cancer prevalence rate may be quite different in 
the Asian population.
 The incidence of endometrial cancer in Korea is increasing 
according to previous research (Fig. 1) (12,13). However, this 
Table 1. Etiology of PMB during 2005–2009 and 2010–2014
Diseases
No. (%) of cases
P value* OR (95% CI)
2005–2009 2010–2014 Total
Atrophy 231 (51.2) 227 (51.1) 458 (51.1) 0.658 0.942 (0.724–1.226)
Polyp 54 (12.0) 49 (11.0) 103 (11.5) 0.643 0.907 (0.602–1.369)
HRT 48 (10.6) 55 (12.3) 103 (11.5) 0.428 1.181 (0.783–1.782)
Cervical cancer 39 (8.7) 23 (5.2) 62 (6.9) 0.048 0.574 (0.337–0.979)
Endometrial cancer 27 (6.0) 24 (5.4) 51 (5.7) 0.695 0.893 (0.507–1.573)
Anticoagulant usage 23 (5.1) 40 (9.0) 63 (7.0) 0.023 1.833 (1.079–3.117)
Others 29 (6.4) 28 (6.3) 57 (6.4) 0.926 0.975 (0.570–1.667)
Total 451 446 897
PMB = postmenopausal bleeding, HRT = hormone replacement therapy, OR = odds ratio, CI = confidence interval.
*P value: Pearson χ2 test.
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study demonstrated that the incidence of PMB caused by en-
dometrial cancer did not show significant change. As indicated 
by cancer statistics in Korea (1993–2012) (12), although the in-
cidence rate increased, the actual number is not substantially 
high. This may explain why there is some disparity between this 
study and the previous ones.
 Among the endometrial cancer patients in the study popula-
tion, the average endometrial thickness (ET) including the mass 
size measured by gynecologic sonography was 48 mm. Sixty-six 
percent of patients were shown to have an endometrial mass 
and 78.7% had ET more than 10 mm (Fig. 2). The percentages 
of patients with ET ≥ 5 mm and < 10 mm, and < 5 mm were 
8.5% and 12.8%, respectively. Various reports debated the most 
sensitive cut-off value for ET to detect endometrial cancer by 
sonography. An optimal cut-off of 5 mm is being proposed (4,18) 
and our data clearly exceeds this limit. Hysteroscopy also aids 
the diagnosis, allowing visual confirmation and endometrial 
biopsy during the procedure, evidently increasing the screen-
ing sensitivity (7,8,10,18). For patients without PMB, the 5 mm 
cut-off could be recommended as described from previous stud-
ies (4,18). However, since this study result reveals that certain 
number of patients with ET less than 5 mm were also found to 
have cancer, biopsy can be considered even in patients with ET 
< 5 mm when PMB coexists. Further prospective studies will 
be needed to confirm this.
 Another notable change that appeared from our results is the 
decreased incidence in cervical cancer over the years. Accord-
ing to several studies (11,12,14,19), both incidence and mortali-
ty rates of cervical cancer in Korea have been declining. In coun-
tries where organized cytological screening has been implement-
ed, such as the US and Korea, this trend has been kept steady 
(Fig. 1). Due to the national cervical cancer screening program 
and the nation’s improved socioeconomic status, early diagno-
sis allowed early treatment, which helped decrease cervical can-
cer mortality. Additionally, human papilloma virus (HPV) vac-
cination was introduced into clinical practice in Korea in 2007, 
which will further help reducing cervical cancer incidence. De-
spite the decreasing trend, Korean age-standardized cervical 
cancer incidence is still higher than the age-standardized inci-
dence of the world population, which may explain why cervical 
cancer was ranked higher in the list of Korean PMB causes. Park 
et al. (11) explained this by the relatively higher proportion of 
the elderly in the Korean population compared to the demogra-
phics of the world population.
 Last, HRT usage was shown to have increasing trend in the 
latter 5-year group. Previous data (20,21) described decreased 
number of HRT users in the post-Women’s Health Initiative (WHI) 
era, however recently in Korea, the number seems to increase 
again with the rising number of tibolone users (Fig. 3). Accord-
ing to the Long-Term Intervention on Fractures with Tibolone 
(LIFT) study (22), invasive breast cancer risk was decreased by 
Fig. 1. Age-standardized incidence curves of cervical and endometrial cancer, Korea Central Cancer Registry, National Cancer Center (12,13).
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Fig. 2. Sonographic characteristics of endometrial cancer patients’ endometrium.
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using tibolone. It was also shown to be as effective as EPT for 
postmenopausal symptoms but without causing as much PMB 
(20,21,23), therefore eventually the number of tibolone users 
continued to increase. From this study population, the latter 
5-year period included more number of tibolone users than the 
first half of the decade (23.6% vs. 18.8%), which also reflects this 
phenomenon. However, as described elsewhere in literature 
(23), EPT is still the most common HRT-related cause of PMB 
and this study population also comprises more of EPT users 
than tibolone. This also may be the reason that the prevalence 
of PMB associated with HRT seems to be stationary although 
the number of women using HRT was previously decreased.
 The limitation of this study is that the study population was 
recruited from a single tertiary medical center. Selection bias 
may be present in this study population since cancer patients 
are mostly converged to tertiary centers to get appropriate med-
ical care. However, the percentage of gynecologic malignancy 
patients was not high enough to make significant difference in 
the high ranking causes of PMB. It would be reasonable to sim-
ply refer to the decreasing prevalence trend over the years. An-
other limitation is that the comparisons between initial and lat-
ter ‘5-year’ groups may be too short of a duration to investigate 
the change of cancer prevalence. Further studies with longer 
follow-ups will be needed to make definite conclusions.
 Meanwhile, the strength of this study is that it was the first to 
evaluate the causes of PMB in an Asian population. Given the 
different ethnic background, the genetic susceptibility to cer-
tain diseases differs among populations. This study clearly re-
vealed different etiologies of PMB in Korean women compared 
to the previous data. Further studies including other Asian na-
tionalities will be needed to confirm our results.
 In conclusion, only the most common cause of PMB was the 
same as in previous data, while other causes were all ranked 
differently in Korean postmenopausal women. Interestingly, 
cervical cancer was noted as the fourth common cause of PMB, 
showing greater percentage than the previous western data. The 
percentage of cervical cancer decreased during the latter half of 
the decade, reflecting the changes in the nation’s cancer preva-
lence rate. Additionally, the use of HRT increased.
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